Company Filing History:
Years Active: 2003-2009
Title: The Innovations of Inventor Mikito Ito
Introduction
Mikito Ito, an accomplished inventor based in Machida, Japan, has made significant contributions to the field of biotechnology. With a remarkable portfolio of five patents, his work is particularly focused on therapeutic innovations targeting the vascular endothelial growth factor (VEGF) pathway, a crucial mechanism in various diseases.
Latest Patents
Among his latest innovations is an anti-human VEGF receptor Flt-1 monoclonal antibody. This invention encompasses an antibody or peptide that immunologically reacts with the human VEGF receptor Flt-1 and the cells expressing it on the surface. The invention also provides an antibody or peptide that inhibits the binding of human VEGF to the receptor. This important development has the potential to serve as a means for diagnosing and treating diseases characterized by abnormal angiogenesis, such as solid tumor proliferation, rheumatoid arthritis, diabetic retinopathy, retinopathy of prematurity, and psoriasis, among others.
Career Highlights
Mikito Ito's career boasts tenure at prominent companies, including Kyowa Hakko Kogyo Co., Ltd. and Kyowa Hakko Kirin Co., Limited. His involvement in these institutions has enriched his expertise and enabled him to foster innovations that contribute valuable advancements in medical biotechnology.
Collaborations
Throughout his career, Mikito Ito has collaborated with notable contemporaries such as Kenya Shitara and Nobuo Hanai. These partnerships have facilitated the exchange of ideas and propelled collaborative innovations in the industry, further solidifying the impact of their combined efforts in scientific research and patent developments.
Conclusion
In conclusion, Mikito Ito stands out as a significant figure in the realm of biotechnology, particularly through his groundbreaking work on VEGF receptor antagonism. His innovative inventions and collaborative projects continue to pave the way for future advancements in the diagnosis and treatment of diseases linked to abnormal angiogenesis. With five patents to his name, his contributions are set to make a lasting impact on healthcare and scientific research.